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When speaking about optical approaches for 
theranostics, that is method that unites diagnosis, 
treatment and preferably treatment guidance in one 
procedure, it is good to recall what light already did 
in medicine as well as to consider the most pressing 
unresolved medical challenges that will benefit from 
new approaches including theranostics. 
Light by itself is a universal form of energy 
(Figure 1) that can be rapidly delivered and converted 
into various medically-relevant forms such as heat, 
chemical and mechanical processes, sound and light, 
all of which are used for diagnosis and various thera-
pies. The historic examples of light doing magic in 
medicine are the invention of the microscope in the 
XVI century [1] and of “bloodless” laser surgery in the 
XX century [2]. 
Present medical practices including surgery, and 
chemo- and radiation-therapies often suffer from an 
inability to remove or kill pathological cells when the 
latter are intertwined with functionally important 
organs and develop resistance to drugs and radiation. 
This forces clinicians to balance the risks of residual 
and recurrent disease with damaging important cells 
and organs, thus further complicating the disease by 
compromising the patient’s quality of life and physi-
ological health. The ultimate solution is to transform 
current macro-treatment into cell level theranostic 
tools which will rapidly and selectively detect and 
destroy only pathological cells while sparing nearby 
normal cells. Unfortunately, such a tool does not yet 
exist, and it is precisely here that the combination of 
light and nanotechnology is most promising. 
 
 
Figure 1. Universal nature of energy delivery by light: from stars to nanoparticles. 
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The recent advances in chemistry allowed to 
employ a phenomenon of plasmon resonance [3] for 
the conversion of light into medically-relevant pro-
cesses at nanoscale via metal (plasmonic) nanoparti-
cles that show a million times higher optical absorb-
ance than any natural molecules. Among them, gold 
nanoparticles have both the highest optical absorb-
ance and the lowest toxicity. Interestingly, gold na-
noparticles are not new. In fact, they were invented by 
Michael Faraday in the XIX century [4] and have been 
used in clinics for more than fifty years [5]. On the 
other hand, recent advances in laser technologies al-
lowed the use of near-infrared continuous and pulsed 
light with the maximal tissue penetration depth (up to 
10 mm [6]) and safety. Fiber optical technologies al-
lowed the delivery of light even deeper, up to 300-400 
mm, thus enabling laser micro-surgery [7]. Finally, 
advances in conjugation chemistry made possible the 
precise delivery of gold nanoparticles to specific 
pathological cells, where these nanoparticles can be 
remotely and instantaneously activated with visible 
or near-infrared laser light. All the above created a 
unique interdisciplinary platform for the develop-
ment and clinical translation of bio-nano-photonics. 
The current issue presents several research and re-
view papers that report both the fundamentals and 
applications of light-activated nanoparticles in biolo-
gy and medicine.  
Diagnostic methods employ optical scattering 
[8-10], luminescence [11] and fluorescence [9, 10] by 
nanoparticles and optical scattering and acoustic sig-
nals by plasmonic nanobubbles [12]. Cell-specific 
targeting and the internalization of nanoparticles 
provided high sensitivity and specificity of the diag-
nosis. Optical detection methods are mostly appro-
priate for in vitro and extra-corporeal applications 
with unlimited optical transparency. Photoacoustic 
methods [13] are better suited to in vivo applications, 
with poor optical transparency of opaque tissues. It is 
worth mentioning one specific animal model, 
zebrafish [14], that combines the physiology of a ver-
tebrate animal with the high optical transparency of in 
vitro samples. 
The therapeutic methods discussed in this issue 
include several groups. Most established laser- and 
gold nanoparticle- therapy employs the photothermal 
effect and delivers cell level hyperthermia [9, 10]. This 
drug-free approach employs continuous lasers and 
gold colloids or specifically engineered near-infrared 
gold nanoparticles such as nanorods, nanoshells and 
others. The limitation of such an approach is in low 
cell specificity due to the unavoidable non-specific 
uptake of nanoparticles by healthy cells and due to 
thermal diffusion during relatively long exposure 
times. Another drug-free approach employs very 
short laser pulses to prevent thermal diffusion and 
instead of heat employs the purely mechanical impact 
of the nanoparticle-generated expanding and col-
lapsing vapor nanobubbles (plasmonic nanobubbles) 
[12, 13]. The threshold nature of plasmonic nanobub-
bles allowed an improvement in their cellular speci-
ficity compared to nanoparticle therapies [8, 12, 13]. 
The next group of therapeutic methods employs 
light-activated nanoparticles for the on-demand re-
lease of encapsulated drugs [10, 11, 15, 16]. Nanopar-
ticle-generated heat melts the membrane of a complex 
nanocarrier within minutes or less, and releases its 
therapeutic payload [15, 16]. Even faster release oc-
curs via the plasmonic nanobubble-induced explosive 
mechanical disruption of the nanocarrier. In this case, 
instead of relatively slow diffusion, the payload is 
ejected from a nanocarrier in mere nanoseconds [13].   
The possibility of combining several agents with 
different functions in one nanocarrier created a new 
class of theranostic nanoparticles [9, 10, 15, 16]. For 
example, liposome or microcapsule may carry an en-
capsulated drug and attached antibodies for targeted 
therapy, gold nanoparticles for heating and fluores-
cent molecules or quantum dots for optical imaging or 
magnetic nanoparticles for magnetic resonance im-
aging. This all-in-one concept is intriguing, although 
the complexity of such theranostic nanoparticles will 
have to deal with the challenges of toxicity and sta-
bility. 
Most of the papers presented in this issue con-
sider cancer as the main target. The aggressive and 
resistant nature of cancer cells often leads to the fail-
ure of standard practices. This is where the new ap-
proaches discussed above can be considered as adju-
vant therapies for improving patients’ survival rates 
and quality of life as well as for making the treatment 
both shorter and less stressful. 
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